Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia
- 1 March 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (3), 352-363
- https://doi.org/10.1158/1541-7786.mcr-19-0619
Abstract
Acute myeloid leukemia (AML) is a disease characterized by uncontrolled proliferation of immature myeloid cells in the blood and bone marrow. The five-year survival rate is approximately 25%, and recent therapeutic developments have yielded little survival benefit. Therefore, there is an urgent need to identify novel therapeutic targets. We previously demonstrated that acid ceramidase (ASAH1, referred to as AC) is upregulated in AML and high AC activity correlates with poor patient survival. Here, we characterized a novel AC inhibitor, SACLAC, that significantly reduced the viability of AML cells with an EC50 of approximately 3 µM across 30 human AML cell lines. Treatment of AML cell lines with SACLAC effectively blocked AC activity and induced a decrease in sphingosine 1-phosphate and a 2.5-fold increase in total ceramide levels. Mechanistically, we showed that SACLAC treatment led to reduced levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing in multiple human AML cell lines. This increased pro-apoptotic Mcl-1S levels and contributed to SACLAC-induced apoptosis in AML cells. The apoptotic effects of SACLAC were attenuated by SF3B1 or Mcl-1 overexpression and by selective knockdown of Mcl-1S. Furthermore, AC knockdown and exogenous C16-ceramide supplementation induced similar changes in SF3B1 level and Mcl-1S/L ratio. Finally, we demonstrated that SACLAC treatment leads to a 37 to 75% reduction in leukemic burden in two human AML xenograft mouse models. Implications: These data further emphasize AC as a therapeutic target in AML and define SACLAC as a potent inhibitor to be further optimized for future clinical development.Other Versions
Funding Information
- NCI (P01CA171983)
- NCI (P30CA044579)
- National Institute of General Medicine Sciences (T32GM007055)
This publication has 54 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaThe New England Journal of Medicine, 2013
- Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesisBlood, 2012
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemiaGenes & Development, 2012
- C6-Ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growthBreast Cancer Research and Treatment, 2011
- Mcl‐1; the molecular regulation of protein functionFEBS Letters, 2010
- Acute Myelogenous Leukemia in Older AdultsThe Oncologist, 2009
- Synthesis and bioevaluation of ω-N-amino analogs of B13Bioorganic & Medicinal Chemistry, 2009
- Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphateBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2008
- SRp30a (ASF/SF2) regulates the alternative splicing of caspase-9 pre-mRNA and is required for ceramide-responsivenessJournal of Lipid Research, 2006
- MCL-1S, a Splicing Variant of the Antiapoptotic BCL-2 Family Member MCL-1, Encodes a Proapoptotic Protein Possessing Only the BH3 DomainJournal of Biological Chemistry, 2000